BASEL LIFE 2018

11–14 September 2018

Congress Center Basel
Switzerland

Peptide therapeutics

Thursday 13 September 2018

10.15 – 16.45

Innovation Forums

Peptide therapeutics

The framework of the Basel Life 2018, we will host the “Peptide Therapeutics Forum 2018” for 2 days on Sept 13, and 14. Similar to previous events, presentations highlight important new insights regarding the drug discovery of peptides including examples for successful development. The first day is dedicated to topics to be addressed more early during peptide optimization, and the second day focuses more on issues related to later-stage development. As in the past, this event is thought to disseminate information on latest news in the broad field of therapeutic peptides and to enable networking of interested parties from academia and industries.

Chairs:
Thomas Vorherr (Novartis, Basel, Switzerland)
Roderich Süssmuth (TU Berlin, Germany)

10.15
Rationalizing the passive membrane permeability of Cyclic Peptides
S. Riniker
ETH Zurich, Zurich, Switzerland

10.45
Positive allosteric modulators for GABAs
Immanuel Lerner (Pepticom, Jerusalem, Israel)

11.45
Employing electronic and structural constraints to advance peptide leads to therapeutic peptide mimic prototypes
William Lubell (University of Montreal, Canada)

12.15
Design of bioactive macrocycles
Andrei Yudin (University of Toronto, Canada)

14.15
Revolutionizing the discovery process of bioactive peptides

15.45
Vulnerability of invasive glioma cells to lysosomal membrane instabilisation
Pirjo Lakkonen (University of Helsinki, Helsinki, Finland)

16.15
Ena/VASP EVH1 domains as possible anti-metastatic targets addressed by structure-optimized polyproline-II secondary structure mimetics
Ronald Kühne (Leibniz Institute for Molecular Pharmacology, Berlin, Germany)

Delhi

Friday 14 September 2018

10.45 – 17.15

Innovation Forums

Peptide therapeutics

The framework of the Basel Life 2018, we will host the “Peptide Therapeutics Forum 2018” for 2 days on Sept 13, and 14. Similar to previous events, presentations highlight important new insights regarding the drug discovery of peptides including examples for successful development. The first day is dedicated to topics to be addressed more early during peptide optimization, and the second day focuses more on issues related to later-stage development. As in the past, this event is thought to disseminate information on latest news in the broad field of therapeutic peptides and to enable networking of interested parties from academia and industries.

Chairs:
Thomas Vorherr (Novartis, Basel, Switzerland)
Roderich Süssmuth (TU Berlin, Germany)

10.45
Unlocking the power of D-peptides
J.N. Francis1, Y. Nishimura2, A. Smith3, D.M. Eckert3, E. Kish-Trier1, D. Wettstein1, A.L. Mueller1, M. Martin2, M.S. Kay3, B.D. Welch1
1Navigen, Inc., Salt Lake City, UT, 2NIAID, NIH, Bethesda, MD, 3University of Utah, Salt Lake City, UT, United States

11.15
Antibody targeted Amanitin Conjugates (ATACs): expanding the ADC Landscape with a new payload targeting RNA Polymerase II
C. Lutz
Project Management, Heidelberg Pharma Research GmbH, Ladenburg, Germany

12.15
68Ga/177Lu-Dotatate as theranostic pair in nuclear medicine
Maurizio Mariani (Advanced Accelerator Applications, Torino, Italy)

12.45
Patient-centric combination therapy and sustain peptide drug delivery for metabolic disease
Ved Srivastava (Intarcia Theraeputics, Boston, United States)

14.45
N-butylpyrrolidinone as green solvent for solid phase peptide synthesis
John Lopez (Novartis Pharma AG, Basel, Switzerland)

15.15
Potential of cell-penetrating peptides for improved drug delivery
I. Neundorf
Department of Chemistry, Institute of Biochemistry, University of Cologne, Cologne, Germany

16.15
Drug delivery systems for peptides
Michael Wagner (Sanofi, Frankfurt, Germany)

16.45
In vitro & In vivo performance criteria of enTRinsic™ dosage form using lipid multi-particulates for oral peptide targeted delivery
Paolo Botti (Lonza, Basel, Switzerland)

Delhi

Main sponsor(s)

Sponsor(s)

Supporter(s)

Similar events